Coeptis Therapeutics

NAQ:COEP · US19207A2078

BiotechnologyX-Small

360° View

Value8

Price/Sales30

Price/Earnings—

Price/Book27

Dividend Yield1

Growth93

Revenue Growth89

Profit Growth27

Capital Growth100

TSR 52w37

Safety94

Leverage73

Liquidity54

Refinancing69

Combined31

Sentiment7

Analyst Opinions—

Pro Holdings1

Opinion Changes—

Market Pulse17

Profile

CountryUSA

IndustryBiotechnology

SizeX-Small

TypePublic Company

ExchangeNASDAQCM

Employees1

Websitecoeptistx.com

ISINUS19207A2078

Last UpdateApr 2, 2026

Index & Theme

HematologyGeneticsInfectious DiseasesHealth DiagnosticsImmunologyStem Cell TherapyNeurologyOncologyCommercialMedicalPharmaceutical

Description

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The biopharmaceutical division focuses on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Thi…

Analysis

Coeptis Therapeutics's 360° View rank of 27 places it below its peer average — better than 27% of its true peers.

It's a growth standout (93) and expensive versus peers (8). On safety it is very well financed (94), and the market shows skeptical sentiment (7). Taken together, its Combined rank of 31 reads as below its peer average.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Coeptis Therapeutics with its peers

Kyverna Therapeutics

NSQ:KYTX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Nkarta

NSQ:NKTX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Fate Therapeutics

NMQ:FATE

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Sana Biotechnology

NSQ:SANA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Mink Therapeutics

NAQ:INKT

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Vir Biotechnology

NSQ:VIR

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →